Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its generic drug, injectable Cefazolin Sodium (0.5g, 1.0g), which has passed the quality and therapeutic consistency evaluation. The approval marks a significant milestone for the company in adhering to high standards of drug production and contributes to its reputation in the pharmaceutical industry.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.